Shereen Elazzazy

7PUBLICATIONS
9CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)ChiropracticPrimary health care
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Feb 23, 2026
Economic evaluation of cyclin-dependent kinases 4 and 6 inhibitors in advanced hormonal receptor-positive and human epidermal growth factor receptor 2 negative breast cancer: a nationwide budget impact analysis.

Shereen Elazzazy, Nour Hisham Al-Ziftawi, Laila Shafei

|Oct 17, 2024
Real-World Data Presenting the Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors (TKIs) Among Metastatic Non-Small-Cell Lung Cancer (mNSCLC) Patients in Qatar: A Nationwide Retrospective Cohort Study.

Rawan Dawoud, Harman Saman, Kakil Rasul

|Jan 08, 2023
Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation.

Nour Hisham Al-Ziftawi, Mohammed Fasihul Alam, Shereen Elazzazy

|Oct 18, 2020
Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review.

Aasir M Suliman, Shaza A Bek, Mohamed S Elkhatim

|Feb 25, 2020
Law, Culture, and Fear: A Qualitative Study of Health Professionals' Perceptions of Narcotic Use Related to Cancer Pain.

Dania Al-Masri, Kerry Wilbur, Shereen Elazzazy

|Nov 14, 2019
Perceptions and expectations of health care providers towards clinical pharmacy services at a tertiary cancer centre in Qatar.

Nabil E Omar, Shereen Elazzazy, Oraib Abdallah

Pageof 2

Frequent Collaborators

2 joint publications

Nabil E Omar

2 joint publications

Anas Hamad

2 joint publications

Mohamed Izham Mohamed Ibrahim

1 joint publications

R Ghasoub